LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

5.35 -2.73

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.28

Max

5.38

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	18.6 108.767
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+76.91% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	297M 945M
Iepriekšējā atvēršanas cena	8.08
Iepriekšējā slēgšanas cena	5.35

Ziņu noskaņojums

By Acuity

57%

43%

284 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. marts 23:35 UTC

Galvenie ziņu notikumi

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026. g. 1. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026. g. 1. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026. g. 1. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026. g. 1. marts 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026. g. 1. marts 23:19 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026. g. 1. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026. g. 1. marts 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026. g. 1. marts 22:55 UTC

Galvenie ziņu notikumi

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026. g. 1. marts 22:54 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026. g. 1. marts 22:53 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026. g. 1. marts 22:38 UTC

Tirgus saruna

Galvenie ziņu notikumi

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026. g. 1. marts 22:21 UTC

Peļņas

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026. g. 1. marts 22:17 UTC

Tirgus saruna

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026. g. 1. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026. g. 1. marts 22:00 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026. g. 1. marts 21:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026. g. 1. marts 21:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026. g. 1. marts 21:30 UTC

Tirgus saruna

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026. g. 1. marts 21:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026. g. 1. marts 21:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026. g. 1. marts 20:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026. g. 1. marts 20:40 UTC

Tirgus saruna

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026. g. 1. marts 20:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

76.91% augšup

Prognoze 12 mēnešiem

Vidējais 9.5 USD 76.91%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

284 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.